Clinical trial
Gemcitabine and Dasatinib in Advanced Solid Tumors
NCT00429234 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00429234 |
|---|---|
| Title | Gemcitabine and Dasatinib in Advanced Solid Tumors |
| Official title | Phase I Open-Labeled Trial of Gemcitabine and Dasatinib in Advanced Solid Tumors |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Cancer, Solid Tumors |
| Intervention type | Drug |
| Interventions | Dasatinib, Gemcitabine |
| Enrollment | 54 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2013 |
| Completion | Feb 1, 2013 |
| First posted | Jan 31, 2007 |
| Last update posted | Apr 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: